

Name of journal: World Journal of Clinical Oncology

Manuscript NO: 58017

Title: Practice change in management of metastatic urothelial carcinoma after ASCO 2020.

Reviewer 1

SPECIFIC COMMENTS TO AUTHORS

Comments to the author

1.3 The author should consistently include the country in the institution part. *It is added in the new article*

“1.7 Abstract Line 10 At ASCO 2020 the results of JAVELIN Bladder 100 phase 3 trial were presented,” This part is hard to understand. Please reconsider and revise it. *It is changed to have a better understanding*

Is “JAVELIN Bladder” a clinical trial name? If so, the author should write a consistently same spell. *The name of the clinical trial is JAVELIN Bladder 100. I have modified the text to use always the same spell*

The author mentioned avelumab as one of the keywords of this editorial. In the abstract and core tip, the author should simply explain the feature of this drug and the relationship of this drug and JAVELIN Bladder trial. *I have added this information in the abstract and core tip*

The author said “The landscape of urothelial carcinoma treatment has changed significantly in the last years. ” in the core tip. Would you like to mention “in the last decades”? The author should specifically explain how long has it taken to shift the new landscape from traditional therapy. *I have change “last years” for “last 5 years”*

2.1 Main Text INTRODUCTION “Urothelial carcinoma is the predominant histologic type, with approximately 90 percent of bladder cancers in the United States and Europe.”

The author needs to add a reference to this sentence. *The reference is added*

“In addition, new drugs, such as immune checkpoint inhibitors (ICI) and targeted agents, have emerged as new therapeutic choices in the last years and have changed the therapy landscape of mUC.” In this sentence, the “targeted agent” should be written molecular targeted agent.” Moreover “in the last years” are vague to explain the transition of the new therapy. *I have changed the sentence*

References 10 and 11 are the website of FDA approval. As an editorial, the author should use any trials or research abstract to this part. Please reconsider and revise those. *I have changed both references.*

Moreover, the author should consistently write the name of drugs small characteristics such as erdafitinib, and enfortumab vedtin. *I have modified the text to have the same spell.*

End of the introduction part, the author should explain the purpose of this editorial clearly. *I have added a comment at the end of the introduction*

“MOST RELEVANT STUDIES PRESENTED AT ASCO 2020 JAVELIN Bladder 100 was one of the most important studies that were presented at ASCO 2020. ---” In this part, the author did not write the reference for this trial. Please check and add the appropriate reference. *The reference of this trial was in the next sentence. I have changed it according to reviewer suggestion.*

The author should use table 1 more effectively to explain the relevant study which showed a new treatment option to mUC. Moreover, the author has to add references to table 1.

I have added the reference to table 1. The JAVELIN Bladder 100 trial is the only phase 3 randomized trial presented at ASCO. These data are described in the table.



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgooffice@wjgnet.com
<https://www.wjgnet.com>

Name of journal: World Journal of Clinical Oncology

Manuscript NO: 58017

Title: Practice change in management of metastatic urothelial carcinoma after ASCO 2020.

Reviewer 2

SPECIFIC COMMENTS TO AUTHORS

The manuscript was well-organized, and the core tips the authors presented are useful for clinicians when using drugs.